文献速递临床免疫

联合NR1-4a活细胞法与NR1/NR2融合固定细胞法优化NMDAR自身抗体检测

Optimized NMDAR autoantibody detection via combined NR1-4a LCBA and NR1/NR2 fusion FCBA.
PubMed 文献 · Clin Chim Acta · 2026-01-08

本研究通过构建NR1或/和NR2B全长、截短及融合蛋白表达载体,在CHO细胞上建立六种细胞法检测模型,用18例抗NMDAR脑炎患者、30例其他神经疾病患者及20例健康对照的血清和脑脊液评估检测效能。结果显示模型IV(NR1-4a单亚基)活细胞法诊断灵敏度达100%,模型V(NR1-1a ATD融合NR2B ATD)固定细胞法技术灵敏度最高,联合检测使血清诊断灵敏度从传统方法83.3%提升至100%。

要点

  • 模型IV活细胞法诊断灵敏度达100%,模型V固定细胞法技术灵敏度最高。
  • 联合模型IV与V检测使血清诊断灵敏度从83.3%提升至100%。
  • 联合检测技术灵敏度较传统模型I显著提高(血清P<0.0001,脑脊液P<0.05)。

核心结论

  • 联合检测模型IV和V显著提高NMDAR抗体检测的准确性和可靠性,为早期诊断和治疗干预提供基础。

研究设计与样本

  • 构建NR1或/和NR2B全长、截短及融合蛋白表达载体,转染CHO细胞建立六种细胞法检测模型(模型I至VI)。
  • 纳入18例抗NMDAR脑炎患者的36份血清和脑脊液样本、30例其他神经疾病患者的血清和脑脊液样本及20例健康对照的血清样本。

主要发现

  • 模型IV(NR1-4a单亚基)活细胞法诊断灵敏度为100%。
  • 模型V(NR1-1a ATD融合NR2B ATD)固定细胞法技术灵敏度最高,显著优于其他模型(P<0.05)。
  • 联合模型IV和V检测使血清诊断灵敏度从传统方法(模型I)的83.3%提升至100%。
  • 联合检测技术灵敏度较模型I显著提高(血清P<0.0001,脑脊液P<0.05)。

关键数值与推荐

  • 模型IV活细胞法诊断灵敏度100%。
  • 模型V固定细胞法技术灵敏度最高,显著优于其他模型(P<0.05)。
  • 联合检测血清诊断灵敏度从83.3%提升至100%。
  • 联合检测技术灵敏度较模型I:血清P<0.0001,脑脊液P<0.05。

临床怎么用

  • 联合使用NR1-4a活细胞法与NR1/NR2融合固定细胞法可提高NMDAR抗体检测的灵敏度和特异性。
  • 该优化检测策略有助于NMDAR脑炎的早期诊断和治疗干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autoimmune encephalitis (AE) is a group of neurological disorders mediated by autoantibodies targeting proteins within the central nervous system, of which anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis is the most common. The current Cell-Based Assay (CBA) that is primarily used to detect NMDAR antibodies in clinical settings, however, exhibits several limitations, including both false-positive and false-negative results. The aim of this research is to improve the sensitivity and specificity of NMDAR antibody detection through optimization of the CBA detection model. METHODS: In this research, recombinant vectors were constructed to express full-length, truncated, and fusion proteins of NMDA Receptor Subunit 1 (NR1) or/and NMDA Receptor Subunit 2B (NR2B). Six distinct models for CBA detection (Model I-Model VI) were established via transfection into CHO cells. A total of 36 serum (SER) and cerebrospinal fluid (CSF) samples from 18 anti-NMDAR patients were analyzed alongside 30 SER and CSF samples from individuals with other neurological disorders and 20 SER samples from healthy controls to systematically evaluate the detection efficacy across each model. RESULTS: The findings indicate that the Model IV (NR1-4a single subunit) exhibited optimal diagnostic sensitivity(true positive identified) at 100% by live cell-based assay (L-CBA). In contrast, Model V (NR1-1a Amino Terminal Domain (ATD) fused with NR2B ATD) displayed the highest technical sensitivity(titer detection limit) by the fixed cell-based assay (F-CBA), which was significantly superior to the other models (P < 0.05). The combined testing of Models IV and V resulted in a substantial enhancement of the overall performance of the assay. Specifically, the sample diagnostic sensitivity of the SER increased from 83.3% of traditional detection method(Model I) to 100% and the technical sensitivity was improved with highly significant difference to Model I(SER: P < 0.0001; CSF: P < 0.05). CONCLUSION: The combined detection established in this research markedly improved both accuracy and reliability in NMDAR antibody detection, effectively addressing the limitations associated with traditional detection methods. This optimized detection provides a robust foundation for early diagnosis and therapeutic intervention in cases of NMDAR encephalitis, thereby enhancing patient prognosis.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. He B, Gan J, Mao J, et al. Optimized NMDAR autoantibody detection via combined NR1-4a LCBA and NR1/NR2 fusion FCBA. Clin Chim Acta. 2026. PMID: 41519219. doi:10.1016/j.cca.2026.120834

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。